Rallybio CORP 8-K filings

Rallybio Corporation announced a merger with Avenzo Therapeutics, Inc., a clinical-stage oncology company, and a concurrent $215 million private placement financing.

Rallybio Corporation announced the termination of its merger agreement with Candid Therapeutics, Inc., and concurrently entered into a new agreement with UCB S.A., securing a $50 million termination fee.

Rallybio Corporation announced the immediate departure of Chief Medical Officer Steven Ryder, M.D., with severance and equity terms tied to the pending merger with Candid Therapeutics.

Rallybio Corporation will merge with clinical-stage Candid Therapeutics, Inc., with Candid's equityholders taking a majority stake and a concurrent $505.5 million financing to fund operations through 2030.

Rallybio Corporation will implement a 1-for-8 reverse stock split of its common stock effective February 6, 2026, following stockholder approval.

Rallybio Corporation announced a net income of $16.0 million for the third quarter of 2025 and extended its cash runway through 2027.

Rallybio Corporation has transferred its listing to the Nasdaq Capital Market, securing an additional 180 days to regain compliance with the minimum bid price requirement.

Rallybio reported second quarter 2025 financial results, highlighted by the advancement of its lead RLYB116 program and a strategic divestiture extending its cash runway into mid-2027.

Rallybio Corporation has sold its interest in the REV102 ENPP1 inhibitor program to Recursion Pharmaceuticals for up to $25 million, including an upfront equity payment, significantly extending Rallybio's cash runway into mid-2027.

Rallybio Corporation has entered into a formal employment agreement with its Chief Medical Officer, Steven Ryder, M.D., outlining his compensation, term, and severance provisions.

Rallybio held its annual shareholder meeting on May 13, 2025, and elected directors and ratified the appointment of Deloitte and Touche LLP as its independent accounting firm.

Rallybio is on track to initiate dosing in the RLYB116 confirmatory PK/PD study in 2Q 2025, with multiple data readouts anticipated in 2H 2025, and holds $54.5 million in cash, cash equivalents, and marketable securities as of March 31, 2025, providing runway into 1H 2027.

Rallybio discontinues its RLYB212 program for FNAIT prevention due to unfavorable pharmacokinetic data from a Phase 2 clinical trial, shifting focus to RLYB116 and other pipeline assets.

Rallybio Corporation amended its sales agreement with TD Cowen, reducing the potential offering size of its common stock from $100 million to $9.55 million.

Rallybio announces its Q4 and full year 2024 financial results, highlighting progress in clinical trials and providing a financial runway into the second half of 2026.

Rallybio Corporation received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement, putting its listing at risk.

Rallybio announced its third quarter 2024 financial results, highlighted by progress in its RLYB212 Phase 2 trial and a reduced cash burn.

Rallybio Corporation reports that Dr. Kush Parmar will resign from the Board of Directors and as Chair of the Nominating and Corporate Governance Committee, effective October 31, 2024.

Rallybio announced its second quarter 2024 financial results, highlighted by a collaboration with Johnson & Johnson and progress in its clinical programs, particularly RLYB212.

Rallybio's Executive Chairman, Martin Mackay, Ph.D., will resign his executive role effective December 31, 2024, and transition to a consulting role starting January 1, 2025.

Rallybio Corporation held its annual shareholder meeting on May 15, 2024, where directors were elected and the appointment of the independent auditor was ratified.

Rallybio is on track to initiate a Phase 2 trial for RLYB212 in pregnant women at higher risk of FNAIT in the second half of 2024, with $94.2 million in cash, cash equivalents, and marketable securities as of March 31, 2024.

Rallybio has entered into a collaboration with Johnson & Johnson to advance therapeutic solutions for pregnant individuals at risk of fetal and neonatal alloimmune thrombocytopenia (FNAIT), receiving an upfront payment and equity investment.

Rallybio announced its fourth quarter and full year 2023 financial results, along with updates on its clinical programs, including the planned initiation of a Phase 2 study for RLYB212 in the second half of 2024.

Rallybio announces a strategic portfolio prioritization and a 45% workforce reduction to focus on its Phase 2-ready clinical programs, RLYB212 and RLYB116, extending its cash runway into mid-2026.